RxDoctor Payments DataLook up a doctor →

Randil Clark, MD

Urology · Coeur D' Alene, IDNPI 1205961182

Payments from drug & device makers

$59,937in general payments, 2019–2025

Across 292 payments — averaging $205.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$54K
  • Astellas Pharma US Inc$876
  • Dendreon Pharmaceuticals LLC$484
  • Johnson & Johnson$443
  • Sumitomo Pharma America, Inc.$430
  • Pfizer$384
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$5,67196%
  • Education$2664%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$59,937 in reported general payments places this provider in the 90th percentile of 55 urology providers in Idaho.

See all urology providers in Idaho

Medicare billing

Part B allowed, 2024
$613,159
Medicare patients
473
Services billed
15,508

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide61$838,582
OrgovyxRelugolix208$538,080
ErleadaApalutamide32$468,735
NubeqaDarolutamide13$167,203
YonsaAbiraterone Acet,submicronized12$121,173
GemtesaVibegron75$60,424
MyrbetriqMirabegron14$15,069
Silodosin153$12,857
Abiraterone Acetate15$10,915
Tamsulosin Hcl305$5,393
Testosterone25$5,156
Methenamine Hippurate21$2,172
Solifenacin Succinate14$1,414
Finasteride47$545
Ciprofloxacin Hcl29$310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$876$853,65175 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$430$598,504283 claims
Johnson & JohnsonErleada$443$468,73532 claims
BayerNubeqa$54,366$167,20313 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$15$10,91515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 55 urology providers in Idaho.

Other urology in Coeur D' Alene

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →